ReviewAntibiotics (Basel, Switzerland)2021
Detection of Multidrug-Resistant
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Genomic insights into multidrug-resistant bacteria: Emergence ofVirulence · 2026Article
- Carbapenem-Resistant Enterobacterales (CRE) in Europe: Surveillance Challenges, Emerging Threats and Public Health Preparedness.Antibiotics (Basel, Switzerland) · 2026Review
- Antimicrobial Stewardship, Laboratory Surveillance, and Quality Management in Africa: A Narrative Review of Challenges and Opportunities for Integrated AMR Control.Health science reports · 2026Article
- Emergence of antimicrobial resistance in New Caledonia: 20-year trends from laboratory-based surveillance (2005-2024).The Lancet regional health. Western Pacific · 2026Article
- Direct-from-Specimen Detection of Major Carbapenemases by Carbapenem-Resistant K.N.I.V.O. Detection K-Set: Comparative Analysis of Accuracy and Turnaround Time.Pathogens (Basel, Switzerland) · 2026Article
- Evaluation of a Novel In Vitro Diagnostic Immunoassay for the Rapid Qualitative Detection of KPC, NDM, OXA-48-like, IMP and VIM Carbapenemases.Diagnostics (Basel, Switzerland) · 2026Article
- Evaluation of the NG-TESTJAC-antimicrobial resistance · 2026Article
- Low-frequency ultrasound-assisted application of Ag/Cu nanocomposites as a promising strategy for the treatment of purulent wounds.Discover nano · 2026Article
- Detection of OXA-23 and OXA-58 inMicrobiology spectrum · 2026Article
- Susceptibility Trends of Enterobacterales Isolated from Blood Culture Samples: A Four-Year Analysis with the Rise of Carbapenem Resistance.Infectious diseases & clinical microbiology · 2026Article
- Occurrence and Genomic Characterization of ESBL-, AmpC-, and Carbapenemase-ProducingMicroorganisms · 2026Article
- Rapid commercial CTX-M diagnostics: Performance, limitations and clinical impact.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Resistance gene profiling of beta-lactamase and carbapenemase in gram-negative blood isolates: A tertiary care hospital.PloS one · 2026Article
- Review
- Diagnostic characteristics of the Rapid ESBL NPEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- A Review on the Current and Future State of Urinary Tract Infection Diagnostics.International journal of molecular sciences · 2025Review
- Understanding Recent Developments in Colistin Resistance: Mechanisms, Clinical Implications, and Future Perspectives.Antibiotics (Basel, Switzerland) · 2025Review
- Comparison of Two Lateral Flow Immunochromatographic Assays for Rapid Detection of KPC, NDM, IMP, VIM and OXA-48 Carbapenemases in Gram-Negatives.Microorganisms · 2025Article
- Genetic diversity, biochemical properties, epidemiology, and detection methods of IMP- and VIM-type carbapenemases.Clinical microbiology reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.